A Morbidity and Mortality Approach to
Guillain-Barré Syndrome

Stephen K Holland, MD
Chief Medical Officer, LTCG

June 11, 2019


View the Webinar - Click Here

Note: A password is required to view webinar videos.
Contact Debbie Maas at dmaas@fuzionanalytics.com.

Program Description and Bio

Description: Guillain-Barré syndrome is the most common and most severe acute paralytic neuropathy, with about 100,000 people developing the disorder every year worldwide. Under the umbrella term of Guillain-Barré syndrome are several recognizable variants with distinct clinical and pathological features and the severe, generalized manifestation of this disease with respiratory failure affects 20–30% of cases. Understanding of the infectious triggers and immunological and pathological mechanisms has advanced substantially in the past 10 years, and new vectors have been discovered - in 2013 and 2014, an increase in the number of cases of the Guillain–Barré syndrome was observed during an outbreak of Zika infection in French Polynesia and later Zika outbreaks have been associated with increased levels of Guillain-Barré cases.

This presentation on Guillain-Barré will include a description of the basics of the disease process, the differences between Guillain-Barré and other neuropathies and the common medications and therapies used to treat Guillain-Barré. In addition, we will identify the important risk factors for Guillain-Barré including the recently discovered Zika-GB connection and what this portends for future disability and dependency, and how to underwrite a history of Guillain-Barré in the past. From a claims standpoint, we will explore the types of disabilities that occur in Guillain-Barré, the role of Care Manager in developing appropriate Plans of Care and we will compare Guillain-Barré to other disabling chronic conditions on how they cause disability and dependency. Finally, we will explore the natural history of this disorder, the potential for recovery and the duration of disability.


MooreStephen K. Holland, MD - LTCG Stephen K. Holland, MD serves as Chief Medical Director for LTCG and brings more than 29 years of long-term care, life and managed care leadership experience. As the clinical leader at LTCG, Dr. Holland has played an integral role in building the underwriting and claim capabilities of the country's largest full service LTC and Life-LTC Insurance Administrator.

Dr. Holland holds a Doctorate of Medicine from the Case Western Reserve University School of Medicine and completed his postgraduate medical training in Internal Medicine at the University of Washington. He completed a fellowship in health care policy as a Robert Wood Johnson Clinical Scholar at the University of Washington, School of Medicine and received his Board Certification in Internal Medicine from the American College of Physicians.